drugset / Trial / NCT00110721
GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients. In this Phase II study, patients with colon cancer which has spread, despite treatment with approved therapies, will receive GM-CT-01 plus 5-FU in monthly cycles for at least 2 cycles or until their disease progresses.
Timeline
- Start
- 2005-05
- Primary completion
- 2007-06
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DAVANAT | Other / unclassified | 280 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 500 mg/m2 | — |